At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
34% of patients with locally advanced disease achieved a complete response (CR) while 17%-21% of metastatic patients achieved a CR The tolerability profile was consistent with earlier analyses, with a low level of high grade immune-related adverse events MUMBAI, India and HOOFDDORP,...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


